Life Extension Magazine®
LE Magazine April 2004 | |||||
Resveratrol Powerful Protection Against Prostate Cancer By Terri Mitchell | |||||
Good news for men concerned about prostate cancer: resveratrol is a supplement that blocks it at every stage, from beginning to end. A polyphenol found in grapes and other plants, resveratrol was first identified as a multistage protector in 1997,1 and now is considered a leading agent against prostate cancer by researchers at Houston’s MD Anderson Cancer Center and other institutions.2,3 Resveratrol works through more than a dozen different anticancer mechanisms and selectively targets cancer cells. This single supplement modulates hormones, has several mechanisms that stop cancer cells from multiplying, and even has the ability to destroy cancer cells. Resveratrol originally gained notice when researchers suggested that it is the agent in wine that protects against heart disease. Because of its antioxidant and anti-inflammatory actions, resveratrol also was investigated as a possible anticancer supplement. Since research began in earnest in the 1990s, resveratrol has been the subject of hundreds of scientific papers, making it one of the most intensely studied supplements on the market today. In one review of resveratrol, University of Wisconsin researchers set out six criteria for a good anticancer agent: it should a) have no toxic effects in healthy cells; b) work against different types of cancers; c) be administered orally; d) have known mechanisms of action; e) be inexpensive; and f) be acceptable to humans.4 Resveratrol met all six criteria. Cancer-Preventive Effects The best approach to cancer is prevention. By augmenting the body’s natural scavenging and repair mechanisms, cancer cells can be prevented from forming and destroyed immediately if they do. If one has been treated for cancer already, preventing recurrence is paramount. Resveratrol is a “chemopreventive” supplement that prevents DNA damage and destroys cancer cells from the earliest to the latest stages in both human and animal experimental models. One remarkable aspect of resveratrol is that it can be very toxic to cancer cells but does not harm healthy cells; in fact, a person taking resveratrol for protection against prostate cancer may receive cardiovascular benefits as a side effect. Another important aspect of resveratrol is that it may be combined with other phytofactors to potentially enhance its effects. Resveratrol naturally occurs with other polyphenols such as quercetin in plants such as grapes. Quercetin may enhance resveratrol’s bioavailability and cancer-killing effects.6,7 Another plant extract, indole-3-carbinol, or I3C, may work synergistically with resveratrol to kill more cancer cells because I3C stops cell growth at one point in the cell cycle while resveratrol stops it at another point.8,9 Physicians employ this same concept when prescribing combinations of chemotherapeutic drugs for their patients—each drug halts cancer cell growth at a different stage of the growth cycle. Researchers who have studied the effects of grape extract containing resveratrol and quercetin in advanced human prostate cancer cells that were transplanted into rodents have proposed these agents as a possible therapy for prostate cancer in humans, though such therapies have not yet been tried.10 After studying the effects of grape seed extract on advanced prostate cancer cells, researchers at the University of Colorado concluded that combining the extract with a natural cancer-killing cytokine (tumor necrosis factor) “might prove to be a more effective and less toxic alternative in clinical therapy of prostate cancer.”3 In another study that examined different types of prostate cancer cells, resveratrol was the most potent of all polyphenols tested against advanced prostate cancer cells.11 Austrian researchers report that resveratrol works through a tamoxifen-like mechanism to block bone cells’ ability to respond to messages from cancer in other parts of the body, potentially preventing cancer from spreading to the bone.12 While resveratrol alone is a powerful polyphenol, combining it with other plant-derived compounds may further enhance its strength. Researchers increasingly are requesting grants to study such combinations of phytocompounds.13 Taking Aim at Hormones Regulating Genes Cutting-Edge Therapeutic Action Neutralizing Carcinogens Resveratrol and its related polyphenols also protect DNA, block cancer-causing chemicals and radiation, and fight free radicals and inflammation. They have been shown to be more powerful against some types of radicals than vitamins C and E.39-41 Resveratrol activates the same anticancer gene activated by non-steroidal anti-inflammatory drugs (NSAIDs).42 In a recent study, resveratrol, along with quercetin and curcumin, emerged as the most powerful anticancer agents from 22 compounds that were subjected to a battery of tests, including their ability to suppress ornithine decarboxylase, scavenge free radicals, and counteract carcinogens. Prostate Cancer and Diet In European countries such as France and Switzerland where cattle hormone implants are banned, the incidence of prostate cancer is 50% less than in the US; in Italy and Greece, it is about 75% below the US rate.58 Italian and Greek men commonly drink red wine, a good source of resveratrol. (Although moderate consumption of red wine may be effective in reducing the risk of prostate cancer, this has not been demonstrated conclusively.) Resveratrol, on the other hand, has multiple, anti-prostate cancer effects. Resveratrol halts the growth of hormone-positive and -negative cancers; works through multiple mechanisms to stop cancer cells from multiplying; is effective from the earliest to the latest stages of cancer; protects DNA from damage; and may inhibit cancer metastasis. Combined with quercetin and the powerful anti-hormonal agent I3C, resveratrol may be the best cancer-preventive approach available today. | |||||
LE Magazine April 2004 |
Resveratrol Powerful Protection Against Prostate Cancer By Terri Mitchell |
References |
1. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997 Jan 10;275(5297):218-20. 2. Stewart JR, Artime MC, O’Brian CA. Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr. 2003 Jul;133(7 Suppl):2440S-2443S. 3. Dhanalakshmi S, Agarwal R, Agarwal C. Inhibition of NF-kappaB pathway in grape-seed extract-induced apoptotic death of human prostate carcinoma DU145 cells. Int J Oncol. 2003 Sep;23(3):721-7. 4. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol. 2003 Jul;23(1):17-28. 5. Chemoprevention Working Group to the American Association for Cancer Research. Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res. October 1, 1999;59(19):4743-58. 6. de Santi C, Pietrabissa A, Mosca F, Pacifici GM. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica. 2000 Nov;30(11):1047-54. 7. ElAttar TM, Virji AS. Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs. 1999 Feb;10(2):187-93. 8. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 2001 May 24;20(23):2927-36. 9. Tyagi A, Agarwal R, Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiprolifera- tion and apoptosis. Oncogene. 2003 Mar 6;22(9):1302-16. 10. Xing N, Chen Y, Mitchell SH, Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. 11. Kampa M, Hatzoglou A, Notas G, et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer. 2000;37(2):223-33. 12. Ulsperger E, Hamilton G, Raderer M, et al. Resveratrol pretreatment desensitizes AHTO-7 human osteoblasts to growth stimulation in response to carcinoma cell supernatants. Int J Oncol. 1999 Nov;15(5):955-9. 13. Milner J, Allison R, Elliott J, et al. Opportunities and challenges for future nutrition research in cancer prevention: A panel discussion. J. Nutr. 2003;133:2502S- 2504S. 14. Meng Q, Yuan F, Goldberg ID, Rosen EM, Auborn K, Fan S. Indole-3-carbinol is a neg- ative regulator of estrogen receptor-alpha signaling in human tumor cells. J Nutr. 2000 Dec;130(12):2927-31. 15. Chang YC, Riby J, Chang GH, Peng BC, Firestone G, Bjeldanes LF. Cytostatic and antiestrogenic effects of 2-(indol-3- ylmethyl)-3,3’-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem Pharmacol. 1999 Sep 1;58(5):825-34. 16. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF. Plant-derived 3,3’-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem. 2003 Jun 6;278(23):21136-45. Epub 2003 Mar 27. 17. Jellinck PH, Newcombe AM, Forkert PG, Martucci CP. Distinct forms of hepatic androgen 6 beta-hydroxylase induced in the rat by indole-3-carbinol and pregnenolone carbonitrile. J Steroid Biochem Mol Biol. 1994 Nov;51(3-4):219-25. 18. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits anti-estrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 1999 Jun;179(3):297-304. 19. Serrero G, Lu R. Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid Redox Signal. 2001 Dec;3(6):969-79. 20. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999 Dec 1;59(23):5892-5. 21. Hsieh TC, Wu JM. Grape-derived chemo preventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res. 2000 Jan-Feb;20(1A):225-8. 22. Narayanan BA, Narayanan NK, Re GG, Nixon DW. Differential expression of genes induced by resveratrol in LNCaP cells: P53- mediated molecular targets. Int J Cancer. 2003 Mar 20;104(2):204-12. 23. Li Y, Li X, Sarkar FH. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr. 2003 Apr;133(4):1011-9. 24. Plant compound kills lung cancer cells. Reuters Health. February 2, 2003. Available at: http://12.31.13.115/HealthNews/ reuters/NewsStory0221200318.htm. Accessed February 26, 2004. 25. Chun KH, Kosmeder JW 2nd, Sun S, et al. Effects of deguelin on the phosphatidylinos- itol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst. 2003 Feb 19;95(4):291-302. 26. Udeani GO, Gerhauser C, Thomas CF, et al. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res. 1997 Aug 15;57(16):3424-8. 27. Murillo G, Salti GI, Kosmeder JW 2nd, Pezzuto JM, Mehta RG. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer. 2002 Dec;38(18):2446-54. 28. Gerhauser C, Lee SK, Kosmeder JW, et al. Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. Cancer Res. 1997 Aug 15;57(16):3429-35. 29. Fang N, Casida JE. Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3380-4. 30. Schneider Y, Vincent F, Duranton B, et al. Antiproliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 2000 Sep 29;158(1):85-91. 31. Wolter F, Turchanowa L, Stein J. Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis. 2003 Mar;24(3):469-74. 32. Malt RA, Kingsnorth AN, Lamuraglia GM, Lacaine F, Ross JS. Chemoprevention and chemotherapy by inhibition of ornithine decarboxylase activity and polyamine synthesis: colonic, pancreatic, mammary, and renal carcinomas. Adv Enzyme Regul. 1985;24:93-102. 33. Bachrach U, Shayovitz A, Marom Y, Ramu A, Ramu N. Ornithine decarboxylase—a predictor for tumor chemosensitivity. Cell Mol Biol (Noisy-le-grand). 1994 Nov;40(7):957-64. 34. Hudson EA, Howells LM, Gallacher-Horley B, Fox LH, Gescher A, Manson MM. Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line. BMC Cancer. 2003 Jan 14;3(1):2. 35. Sharma S, Stutzman JD, Kelloff GJ, Steele VE. Screening of potential chemopreventive agents using biochemical markers of car- cinogenesis. Cancer Res. 1994 Nov 15;54(22):5848-55. 36. Stellman SD, Takezaki T, Wang L, et al. Smoking and lung cancer risk in American and Japanese men: an international case- control study. Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1193-9. 37. Wynder EL, Taioli E, Fujita Y. Ecologic study of lung cancer risk factors in the U.S. and Japan, with special reference to smok- ing and diet. Jpn J Cancer Res. 1992 May;83(5):418-23. 38. Lee IP, Kim YH, Kang MH, Roberts C, Shim JS, Roh JK. Chemopreventive effect of green tea (Camellia sinensis) against cigarette smoke-induced mutations (SCE) in humans. J Cell Biochem Suppl. 1997;27:68-75. 39. Zhao J, Wang J, Chen Y, Agarwal R. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3’-gallate as the most effective antioxidant constituent. Carcinogenesis. 1999 Sep;20(9):1737-45. 40. Dubuisson JG, Dyess DL, Gaubatz JW. Resveratrol modulates human mammary epithelial cell O-acetyltransferase, sulfo transferase, and kinase activation of the het- erocyclic amine carcinogen N-hydroxy-PhIP. Cancer Lett. 2002 Aug 8;182(1):27-32. 41. Damianaki A, Bakogeorgou E, Kampa M, et al. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem. 2000 Jun 6;78(3):429-41. 42. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis. 2002 Mar;23(3):425-34. 43. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst. 2000 Jan 5;92(1):61-8. 44. Jain MG, Hislop GT, Howe GR, Ghadirian P. Plant foods, antioxidants, and prostate cancer risk: findings from case-control stud- ies in Canada. Nutr Cancer. 1999;34(2):173-84. 45. Rodler I, Zajkas G. Hungarian cancer mortality and food availability data in the last four decades of the 20th century. Ann Nutr Metab. 2002; 46(2):49-56. 46. Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):795-804. 47. Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer. 2002;42(1):1-9. 48. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Dairy products, calcium, and prostate cancer risk in the Physicians’ Health Study. Am J Clin Nutr. 2001 Oct;74(4):549-54. 49. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control. 2001 Aug;12(6):557-67. 50. Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer. 1997 Nov 27;73(5):634-8. 51. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9. 52. Willett W. Lessons from dietary studies in Adventists and questions for the future. Am J Clin Nutr. 2003 Sep;78(3 Suppl):539S-543S. 53. Mettlin C, Selenskas S, Natarajan N, Huben R. Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study. Cancer. 1989 Aug 1;64(3):605-12. 54. Ankley GT, Jensen KM, Makynen EA, et al. Effects of the androgenic growth promoter 17-beta-trenbolone on fecundity and reproductive endocrinology of the fathead min- now. Environ Toxicol Chem. 2003 Jun;22(6):1350-60. 55. Saartok T, Dahlberg E, Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone- binding globulin. Endocrinology. 1984 Jun;114(6):2100-6. 56. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihy- droxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993 May;132(5):1952-60. 57. Reiling BA, Johnson DD. Effects of implant regimens (trenbolone acetate-estradiol administered alone or in combination with zeranol) and vitamin D3 on fresh beef color and quality. J Anim Sci. 2003 Jan;81(1):135-42. 58. Globocan 2000: cancer incidence, mortality and prevalence worldwide [CD-ROM]. International Agency for Research on Cancer, World Health Organization; 2001. |